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Abstract
Background: Primary prevention of acute rheumatic fever is achieved by proper antibiotic treatment of group 
A b -hemolytic streptococcal (GAS) pharyngitis. Methods: To assess noninferiority of oral amoxicillin to intramuscular 
benzathine penicillin G (IM BPG). Children (2 to 12 years) meeting enrollment criteria were randomized 1:1 to 
receive antibiotic treatment in 2 urban outpatient clinics in Egypt and Croatia. Results: A total of 558 children 
(Croatia = 166, Egypt = 392) were randomized, with 368 evaluable in an intention-to-treat (ITT) analysis, and 272 
evaluable in the per protocol (PP) analysis. In Croatia, ITT and PP treatment success rates were comparable for 
IM BPG and amoxicillin (2.5% difference vs 1.1% difference, respectively). In Egypt, amoxicillin was not comparable 
with IM BPG in ITT analysis (15.1% difference), but was comparable in PP analysis (-9.3% difference). Conclusion: If 
compliance is a major issue, a single dose of IM BPG may be preferable for treatment of GAS pharyngitis.
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Introduction
Primary prevention of acute rheumatic fever (ARF) is 
accomplished by proper identification and antibiotic 
treatment of group A b-hemolytic streptococcal (GAS) 
pharyngitis.1-4 ARF results from an autoimmune response 
to infection with group A streptococcus and its sequelae, 
rheumatic heart disease (RHD), the most common cause 
of acquired cardiac disease worldwide.5 In affluent popu-
lations, ARF is now rare with an annual incidence esti-
mated at 0.5 cases per 100 000 school-age children. In 
contrast, ARF remains an endemic disease in developing 
countries, with annual incidence rates ranging from 100 
to 200 per 100 000 school-aged children and is a major 
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cause of cardiovascular mortality.6 Antibiotic therapy 
can shorten the clinical course of GAS pharyngitis and 
prevent suppurative complications. However, the pri-
mary objective of antibiotic therapy is eradication of the 
GAS organism from the pharynx, which is necessary for 
prevention of ARF.1,7,8
In the 1950s, several studies demonstrated the effi-
cacy of parenteral penicillin in the prevention of ARF in 
military recruits with tonsillitis.2,9-15 Since then, penicil-
lin (either oral penicillin V or injectable benzathine pen-
icillin) has remained the treatment of choice because it is 
cost-effective, has a narrow spectrum of activity, long-
standing proven efficacy, and to date, penicillin-resistant 
GAS has not been documented. The World Health 
Organization, the American Heart Association, and the 
Infectious Diseases Society of America (IDSA) recom-
mend oral penicillin V 2 to 4 times a day for 10 full days 
or a single intramuscular injection of benzathine benzyl-
penicillin in patients without penicillin allergy.16-18 Oral 
antibiotics provide some advantages over parenteral treat-
ment by reducing patient discomfort, needle-associated 
complications, providing shorter exposure to the medi-
cation, and less severe allergic reactions; however adher-
ence to the prescribed oral treatment regimen is critical 
for treatment success. Thus, IM BPG is the preferred 
treatment for patients who are unlikely to complete a 
full 10-day course of oral therapy.17,19,20
Recent studies have suggested that a single daily 
dose of oral amoxicillin for 10 days may be as effica-
cious as oral penicillin V 2 to 3 times daily for 10 days.21-24 
Amoxicillin is globally available, well-tolerated, and 
inexpensive, thus a single daily dose of amoxicillin may 
present a cost-effective and convenient alternative to oral 
or injectable penicillin in both high- and low-resource 
settings.
To date, there are no published reports in the litera-
ture directly comparing amoxicillin with injectable ben-
zathine penicillin for treatment of GAS pharyngitis. 
Additionally, although the burden of ARF/RHD is 
largely in low- and middle-income countries, few clini-
cal studies have been undertaken to assess treatment 
options for GAS pharyngitis in these regions. Thus, we 
compared the microbiological efficacy of a single intra-
muscular injection of penicillin with a 10-day daily dose 
of oral amoxicillin for the treatment GAS pharyngitis in 
children in low-resource clinical settings.
Materials and Methods
This randomized, open label multicenter clinical trial—
known as the Treatment of Pharyngitis Study (TOPS)—
was nested in a larger descriptive study designed to 
evaluate signs and symptoms of GAS pharyngitis in 
children and develop new clinical guidelines for diagno-
sis of GAS pharyngitis in low-resource settings without 
a laboratory. Data from this study describing differences 
in presentation of GAS pharyngitis have been published 
elsewhere.25,26
Patients
Between August 2001 and April 2003, children between 
the ages of 2 and 12 years presenting to outpatient clin-
ics in Cairo, Egypt and Zagreb, Croatia with complaint 
of sore throat were enrolled in the parent descriptive 
study after informed consent.26 Children were excluded 
if the parent/guardian reported oral antibiotic use in the 
past 3 days or injectable penicillin in past 28 days prior 
to screening, had a history of rheumatic fever or rheu-
matic heart disease, required hospitalization for any rea-
son at the time of enrollment, or had previously been 
enrolled in the study.
After enrollment, a physical examination was per-
formed, demographic and clinical data were collected, 
and 2 throat swabs were simultaneously obtained for stan-
dard throat culture and immediate GAS screening using a 
rapid antigen detection kit. Patients with a positive rapid 
test were offered enrollment in the TOPS substudy. Chil-
dren with a known hypersensitivity to penicillin or likely 
to require treatment with other antimicrobials during the 
study period were excluded at the time of enrollment. 
Children with a positive rapid antigen detection test and 
negative throat culture completed their prescribed treat-
ment regimen, however, were excluded from the trial.
Study Design
Patients were randomized to receive oral amoxicillin 
suspension (750 mg once a day for all weight categories) 
given once daily for 10 days or a single dose of intra-
muscularly administered benzathine penicillin G (IM 
BPG; 600 000 units if body weight <27 kg; 1.2 million 
units if body weight ≥27 kg). All drugs distributed to 
patients were obtained from local sources in Egypt and 
Croatia. Parents/guardians of children in the amoxicillin 
arm were instructed to administer the antibiotic at the 
same time every day for 10 days. All patients were 
scheduled for a follow-up visit (days 21-28), during 
which a physical examination and repeat throat culture 
were performed. Compliance, adverse events and drug 
tolerability were also assessed by parental report during 
this visit.
In each study site, participants were stratified by age 
(2 to 5 years and >5 years) and randomly assigned on a 
1:1 basis (with permuted blocks of 6 to 10) to a treatment 
group by sequential selection from a random number 
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table. Treatment allocation results generated by the 
study coordinator in Baltimore and shipped in presealed 
envelopes to study sites. Randomization results were 
kept in sealed envelopes and all study team members 
were blinded from the contents until treatment adminis-
tration. Because of obvious differences in routes of treat-
ment administration, masking of patients and physicians 
was not feasible. However, the primary endpoints were 
objective microbiologic measures that were analyzed by 
laboratory personnel blinded to the treatment.
This study was conducted in accordance with Good 
Clinical Research Practice guidelines and the Declara-
tion of Helsinki. The study protocol, questionnaires, and 
informed consent forms were approved by both local 
and national ethics committees at participating clinical 
sites, the World Health Organization (WHO), and the 
Committee on Human Research at the Johns Hopkins 
Bloomberg School of Public Health. Informed consent 
was obtained from a parent or legal guardian and child 
assent was obtained from all children aged 5 years or 
older. All study sites used a common study protocol and 
data collection forms which were translated into local 
language.
Outcome Measures
The primary outcome of the study was bacteriologic 
treatment success, which was defined as eradication of 
GAS from the pharynx at the follow-up visit. Eradication 
was defined as no GAS present on the throat culture. 
Compliance with the amoxicillin treatment regimen was 
assessed at the follow-up visit. Parents/guardians were 
given a Whatman no. 3 filter paper strip and asked to dip 
it into the child’s urine once on the seventh day of treat-
ment, allow it to air dry, place it in an envelope and bring 
it back to the clinic at the follow-up visit. Filter strips 
were analyzed for antimicrobial activity using a modifi-
cation of the technique of Markowitz and Gordis.27 The 
primary measure of compliance was the presence of anti-
microbial activity in the urine-impregnated filter paper 
strips. For those who did not return the filter paper strip, 
compliance was measured by parent/guardian report dur-
ing the exit interview. Patients who did not fulfill at least 
one of these criteria were considered noncompliant.
Laboratory Methods
Two throat swabs were simultaneously obtained from 
each patient for both culture and rapid antigen assay 
using sterile cotton-tipped swabs. Throat culture speci-
mens were plated on 5% sheep blood agar plates and 
incubated anaerobically at 37.0°C and examined at 24 
and 48 hours for the presence of b-hemolytic streptococci 
and confirmed by bacitracin disc.28 The rapid test (Strep 
OIA MAX; Biostar Laboratories, Denver, CO) was per-
formed according to the instructions in the manufactur-
er’s package insert by trained study personnel. This 
rapid test had internal positive and negative controls and 
has a reported sensitivity range of 79.5% to 98.1% and 
specificity of 96.9% to 99.0%, compared with throat 
culture.29-33 Both sites independently were provided 
with uniform training and regular site visits to ensure 
uniform laboratory procedures for both throat culture 
and rapid tests.
Statistical Methods
Assuming no difference in the treatment effect of the 2 
study arms and a 90% eradication rate, we estimated 
that a sample size of 154 patients per treatment arm 
would have 80% power to demonstrate non-inferiority 
(defined as the upper 95% confidence limit of the treat-
ment effect difference of <10%). Thus, if the treatment 
success for IM BPG was 90.0%, amoxicillin success 
would fall between 80.0% and 90.0% to be considered 
noninferior. For both the intent-to-treat (ITT) and per-
protocol (PP) analysis, we were unable to reach the esti-
mated sample size in each country, thus may not have 
had the power to detect a difference between treatment 
groups between countries.
Differences in discrete variables (GAS positivity rates, 
gender, and dichotomized age) were evaluated with 
2-way contingency tables. Differences in continuous 
variables (age, weight, temperature) were tested using 
Student t tests. P < .05 (2-tailed) was considered signifi-
cant. Logistic regression methods were used to compare 
crude risk difference between treatments, risk difference 
measures adjusted for age and gender in both the ITT and 
PP analysis, and compliance in the PP analysis for the 
outcome of treatment success. Data analyses were con-
ducted using SAS v 9.1 and STATA 10.0 software.34,35
Analysis Groups
The ITT analysis included all patients who were enrolled 
in the study meeting the inclusion and exclusion criteria. 
The PP analysis included all patients in the ITT group 




A total of 558 children (Croatia n = 166, Egypt n = 392) 
were randomized to receive IM BPG or oral amoxicillin 
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(Figure 1). Patients with discordant (negative) throat 
culture results from the initial visit were excluded from 
the trial, thus 121 patients in Croatia and 247 patients in 
Egypt were included in the ITT analysis. A total of 111 
patients in Croatia and 161 in Egypt were classified as 
compliant and were eligible for the PP analysis (Table 1). 
Within countries, the demographic and clinical charac-
teristics for patients were similar in both treatment arms; 
however, those in Croatia were more likely to be included 
in the analysis.
Treatment Success
In the ITT analysis, the difference in bacteriologic treat-
ment success between the 2 antibiotic regimens varied 
by country. In Croatia, amoxicillin was not inferior to 
IM BPG, with no differences observed when further 
controlled by age and gender (2.5% difference, 95% 
confidence interval [CI]: -13.8, 18.9; Table 2). In Egypt, 
amoxicillin continued to be inferior to IM BPG after 
controlling for age and gender (-15.1% difference, 95% 
CI: -26.6, -3.5). Furthermore, in the PP analysis 
(excluding noncompliant patients), amoxicillin was not 
inferior to IM BPG in Croatia (1.1% difference, 95% CI: 
-16.2, 18.5), but remained inferior in Egypt, although 
no longer significant (-9.3% difference, 95% CI: -26.3, 
7.8). When looking at specific stratum differences, the 
largest treatment difference (in favor of IM BPG) was 
seen in Egyptian girls younger than 5 years (38.2%, P < 
.001). However, this difference was no longer signifi-
cant in the PP analysis, once compliance was controlled 
for (data not shown).
Treatment Compliance
Adherence to the amoxicillin treatment regimen varied 
significantly by country: In Croatia, 84.4% were classi-
fied as compliant by either detection of antimicrobial 
Figure 1. Flow diagram of enrollment and inclusion into the Treatment of Pharyngitis Study (TOPS) trial (E, Egypt; C, Croatia)
Assessed for Eligibility
(n = 2046)
E: n = 1642  C: n = 404
Randomized (n = 558)
(Stratified by age and site)
E: n = 392  C: n = 166
Excluded from Study (n = 1488)
Did not meet inclusion criteria (n = 1466)
Allergy to Penicillin (n = 4)
Other (n = 18)
E: n = 1250  C: n = 238
IM BPG (n = 275)
E: n = 191  C: n = 84
Amoxicillin (n = 283)
E: n = 201  C: n = 82
Intent to treat analysis:
Amoxicillin (n = 187)
E: n = 123  C: n = 64
Per Protocol analysis:
IM BPG (n = 181)
E: n = 124  C: n = 57
Per Protocol analysis:
Amoxicillin (n = 91)
E: n = 37  C: n = 54
Loss to follow-up: (n = 74)
E: n = 61  C n = 13
(–) Throat Culture at 1st
visit: (n = 22)
E: n = 17  C: n = 5
Loss to follow-up (n = 65)
E: n = 47  C: n = 18
(–) Throat Culture at 1st
visit: (n = 29)
E: n = 20  C: n = 9
Non-Compliant = N/A
Non-Compliant: n = 96
E: n = 86  C: n = 10
Intent to treat analysis:
IM BPG (n = 181)
E: n = 124  C: n = 57
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activity on the filter strip or patient report as compared 
to 30.1% in Egypt (P < .001; Table 3). In all strata (age 
and gender), children in Croatia were significantly more 
likely to be classified as compliant (P < .001). There 
were no observed differences in adherence by age or 
gender within countries.
Tolerability
Treatment-related adverse events occurred in 5.3% 
(10/187) of the patients in the amoxicillin arm, includ-
ing skin rash 1.6% (3/187), diarrhea 1.6% (3/187), vom-
iting 0.5% (1/187), extreme sweating 0.5% (1/187), 
itching 0.5% (1/187), and nausea 0.5% (1/187). In the 
IM BPG group, 67.4% (122/181) reported discomfort at 
the site of injection. None of the adverse events required 
hospitalization, stopping the treatment regimen, medical 
attention, or withdrawal from the trial.
Discussion
Our study was designed to assess whether oral amoxicil-
lin was not inferior to the long-standing recommended 
therapy of IM BPG in a low- and middle-income country 
setting. We found significant intersite variation in treat-
ment success rates for both antibiotic regimens that were 
likely to be largely influenced by differences in patient 
compliance with the oral amoxicillin treatment regimen. 
In Croatia, the vast majority of patients were compliant 
with the oral treatment regimen; however, in Egypt, patient 
Table 1. Patient Characteristics by Treatment Group
Patient Characteristics
Croatia (n = 166) Egypt (n = 392)
IM BPG Amoxicillin IM BPG Amoxicillin
Patients enrolled; n (%) 84 (50.6) 82 (49.4) 191 (48.7) 201 (51.3)
GAS + by throat culture; n (%) 71 (82.6) 76 (92.7) 154 (80.6) 162 (80.6)
Age in years; n (%)
 <5 32 (38.1) 34 (41.5)  84 (44.0)  88 (43.8)
 ≥5 years 52 (61.9) 48 (58.5) 107 (56.0) 113 (56.2)
Gender; n (%)
 Male 55 (65.5) 46 (56.1) 115 (60.2) 112 (55.7)
 Female 29 (34.5) 36 (43.9)  76 (39.8)  89 (44.3)
Mean age in years ± SD  5.6 ± 2.6  5.7 ± 2.4  5.3 ± 2.6  5.4 ± 2.5
Mean weight in kg ± SD 23.4 ± 9.1 24.0 ± 8.1 19.5 ± 7.4 18.9 ± 6.1
Mean temperature in °C ± SD 37.1 ± 0.8 37.6 ± 0.9 37.9 ± 0.9 37.7 ± 0.8
Intent to treat analysis; n (%) 57 (67.9) 64 (78.0) 124 (64.9) 123 (61.2)
Per protocol analysis; n (%) 57 (67.9) 54 (65.9) 124 (64.9)  37 (18.4)
Abbreviations: IM BPG, intramuscular benzathine penicillin G; GAS, group A b-hemolytic streptococcal; SD, standard deviation.
Table 2. Bacteriological Treatment Success by Country
Country











Intention to treat analysis
 Croatia (n = 121) 70.3 (45/64) 66.7 (38/57) 3.6 -12.9, 20.2 2.5 -13.8, 18.9
 Egypt (n = 247) 61.8 (76/123) 75.8 (94/124) -14.0c -25.5, -2.59 -15.1c -26.6, -3.4
Per protocol analysis
 Croatia (n = 111) 68.5 (37/54) 66.7 (38/57) 1.8 -15.6, 19.3 1.1 -16.2, 18.5
 Egypt (n = 161) 67.6 (25/37) 75.8 (94/124) -8.2 -25.1, 8.6 -9.3 -26.3, 7.8
Abbreviations: IM BPG, intramuscular benzathine penicillin G; 95% CI, 95% confidence interval.
aDifference in percentage success rates (amoxicillin - IM BPG).
bAdjusted analysis: intention to treat, controlled for age and gender; per protocol, controlled for compliance, age, and gender (amoxicillin - 
IM BPG).
cStatistically significant: treatment difference P = .016; adjusted treatment difference P = .011.
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compliance was extremely low. The differences in the 
results of the ITT analysis reflect this discrepancy 
between sites. In Croatia, amoxicillin was not inferior to 
IM BPG in both the ITT and PP analyses. In Egypt, 
amoxicillin was inferior to IM BPG in the ITT but not 
the PP analyses; however, in all analyses, children who 
received IM BPG still had higher treatment success rates 
than those who were treated with amoxicillin.
Treatment success rates for the amoxicillin regimen 
were much lower than initially expected. Studies of 
once daily amoxicillin have reported treatment success 
rates ranging from 94.5% to 100.0%; in our study, treat-
ment success ranged from 61.8% in Egypt to 70.3% in 
Croatia.21-24 Recent publications evaluating the effec-
tiveness of IM BPG for GAS treatment have shown 
decreased rates reported in the range of 65% to 70%, 
which are comparable to our study, which ranged from 
66.7% (Croatia) to 75.8% (Egypt).37 Additionally, our 
findings are consistent with recent reports of reduced 
microbiologic efficacy of both penicillin V and IM BPG 
in children with acute pharyngitis.38-40 To date, there 
have been no reports of penicillin-resistant GAS; how-
ever, the continued decline in treatment success with 
penicillin should be monitored.
Compliance with the amoxicillin treatment regimen 
is likely to be a major driver in the high rates of treat-
ment failure in patients in Egypt. High rates of asymp-
tomatic GAS carriage in Egyptian populations as 
compared to Croatia also have an impact on treatment 
success, since carriers are likely to continue to test posi-
tive for GAS despite treatment.37
Several limitations of the study may have affected 
our results and deserve mention. Because of financial 
constraints, we were unable to conduct M protein gene 
(emm) typing to identify GAS subtypes before and after 
therapy. Thus, it is possible that some patients who may 
have been reinfected after successful eradication of the 
initial infection were misclassified as treatment failures. 
Similarly, we were unable to conduct serologic analyses 
that would have allowed us to classify those patients 
who failed treatment as carriers. However, both carriers 
and those who reacquired GAS after successful treat-
ment should have been equally distributed between the 
2 treatment groups and therefore the observed treatment 
difference between regimens should not have been 
affected. Additionally, although we used a randomized, 
controlled design, both patients and clinicians were 
aware of the study assignments. Another limitation in 
our study was that both study drugs were obtained locally 
rather than from a central source, which could have resulted 
in differences in microbiologic efficacy of either treat-
ment regimen between countries.
Finally, the power of this study to demonstrate statis-
tically significant noninferiority of amoxicillin to IM 
BPG is limited by the sample size, which was inade-
quate because of high loss to follow up in both study 
sites. Although our study is underpowered, our findings 
add to the body of evidence that suggest that amoxicillin 
may provide an effective, well-tolerated treatment for 
GAS pharyngitis without the safety issues associated 
with a penicillin injection. Our study also highlights the 
importance of compliance and the extent to which it 
may be a problem, particularly in low-resource settings. 
Thus, in settings where compliance remains a major 
concern, a single dose of IM BPG may be preferable for 
the treatment of GAS pharyngitis.
In some countries, there is resistance to using injectable 
penicillin because of the perceived higher risk of anaphy-
laxis and the discomfort of intramuscular injections.8 
However, more than 50 years of experience with penicil-
lin has shown that although toxic reactions to intramuscu-
lar penicillin have been reported, severe reactions are 
exceedingly rare, especially in children.16,19 In our study, 
we did not observe any severe reactions to IM BPG.
When selecting an antibiotic regimen for the treat-
ment of GAS pharyngitis, clinicians will consider vari-
ous factors, including availability, bacteriologic and 
clinical efficacy, ease, and likelihood of patient adher-
ence to the treatment regimen (based on frequency and 
duration of administration and palatability), cost, spec-
trum of antimicrobial activity, and potential side effects. 
There is no single antibiotic regimen that is 100% effec-
tive in eradicating GAS from the pharynx; thus there are 
multiple factors that will guide therapeutic choice. 





Croatia (n = 64) Egypt (n = 123)
Compliance 
 measuresa
54 (84.4) 37 (30.1)
 Positive urine 
 filter strip only
2 (3.7) 0 (0.0)
 Parent report 
 only
2 (3.7) 0 (0.0)
 Both measures 
 of compliance
50 (92.5) 37 (100.0)
Gender
 Boysa 33/39 (84.6) 18/65 (27.7)
 Girlsa 21/25 (84.0) 19/58 (32.8)
Age (years)
 <5a 22/24 (91.7) 17/57 (29.8)
 ≥5a 32/40 (80.0) 20/66 (30.6)
aStatistical significance (P < .05) associated with the treatment 
compliance between sites.
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Recent studies have explored short course (3 to 6 days) 
treatments, which may be more convenient and improve 
compliance.41 These shorter course therapies should be 
considered and tested in low-resource settings, particu-
larly in regions where ARF continues to be a major pub-
lic health concern.
Authors’ Note
Dr Shamim Qazi is a staff member of the World Health 
Organization. The expressed views and opinions in this 
manuscript do not necessarily express the policies of the 
World Health Organization.
Declaration of Conflicting Interests
The author(s) declared no conflicts of interest with 
respect to the authorship and/or publication of this 
article.
Funding
The authors disclosed receipt of the following financial 
support for the research and/or authorship of this article:
This study was supported by USAID and the World 
Health Organization.
References
 1. Catanzaro FJ, Rammelkamp CH Jr, Chamovitz R. Pre-
vention of rheumatic fever by treatment of streptococcal 
infections. II. Factors responsible for failures. N Engl J 
Med. 1958;259:53-57.
 2. Denny FW, Wannamaker LW, Brink WR, Rammelkamp 
CH Jr, Custer EA. Prevention of rheumatic fever: treat-
ment of the preceding streptococcic infection. JAMA. 
1950;143:151-153.
 3. Rammelkamp CH, Wannamaker LW, Denny FW. The 
epidemiology and prevention of rheumatic fever. Bull N 
Y Acad Med. 1952;28:321-334.
 4. Stollerman GH. Factors that predispose to rheumatic 
fever. Med Clin North Am. 1960;44:17-28.
 5. Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic 
fever. Lancet. 2005;366:155-168.
 6. Carapetis JR, Steer AC, Mulholland EK, Weber M. The 
global burden of group A streptococcal diseases. Lancet 
Infect Dis. 2005;5:685-694.
 7. Shulman ST. Complications of streptococcal pharyngitis. 
Pediatr Infect Dis J. 1994;13(1 Suppl 1):S70-S74.
 8. WHO/ISFC. Strategy for controlling rheumatic fever/
rheumatic heart disease, with emphasis on primary pre-
vention: memorandum from a joint WHO/ISFC meeting. 
Bull World Health Organ. 1995;73:583-587.
 9. Houser HB, Wannamaker LW, Rammelkamp CH, et al. 
Prophylaxis of acute rheumatic fever by treatment of the 
preceding streptococcal infection with various amounts 
of penicillin. J Lab Clin Med. 1950;36:839.
10. Bennike T, Brochner-Mortensen K, Kjaer E, Skadhauge K, 
Trolle E. Penicillin therapy in acute tonsillitis, phlegmon-
ous tonsillitis and ulcerative tonsillitis. Acta Med Scand. 
1951;139:253-274.
11. Bland EF, Duckett Jones T. Rheumatic fever and rheu-
matic heart disease: a twenty year report on 1000 patients 
followed since childhood. Circulation. 1951;4:836-843.
12. Wannamaker LW, Rammelkamp CH Jr, Denny FW, et al. 
Prophylaxis of acute rheumatic fever by treatment of the 
preceding streptococcal infection with various amounts 
of depot penicillin. Am J Med. 1951;10:673-695.
13. Denny FW, Wannamaker LW, Hahn EO. Comparative 
effects of penicillin, aureomycin and terramycin on strep-
tococcal tonsillitis and pharyngitis. Pediatrics. 1953;11: 
7-13.
14. Chamovitz R, Catanzaro FJ, Stetson CA, Rammelkamp 
CH Jr. Prevention of rheumatic fever by treatment of 
previous streptococcal infections. I. Evaluation of benza-
thine penicillin G. N Engl J Med. 1954;251:466-471.
15. Brumfitt W, Slater JD. Treatment of acute sore throat with 
penicillin: a controlled trial in young soldiers. Lancet.
1957;272:8-11.
16. Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, 
Schwartz RH. Practice guidelines for the diagnosis 
and management of group A streptococcal pharyngitis. 
Infectious Diseases Society of America. Clin Infect Dis. 
2002;35: 113-125.
17. Gerber MA, Baltimore RS, Eaton CB, et al. Preven-
tion of rheumatic fever and diagnosis and treatment of 
acute Streptococcal pharyngitis: a scientific statement 
from the American Heart Association Rheumatic Fever, 
Endocarditis, and Kawasaki Disease Committee of the 
Council on Cardiovascular Disease in the Young, the 
Interdisciplinary Council on Functional Genomics and 
Translational Biology, and the Interdisciplinary Council 
on Quality of Care and Outcomes Research: endorsed 
by the American Academy of Pediatrics. Circulation. 
2009;119: 1541-1551.
18. World Health Organization. WHO Expert Consultation 
on Rheumatic Fever and Rheumatic Heart Disease. In: 
Rheumatic Fever and Rheumatic Heart Disease: Report 
of a WHO Expert Consultation, Geneva October 29 to 
November 1, 2001. Geneva, Switzerland: World Health 
Organization.
19. Robertson KA, Volmink JA, Mayosi BM. Antibiotics for 
the primary prevention of acute rheumatic fever: a meta-
analysis. BMC Cardiovasc Disord. 2005;5:11.
20. Baltimore RS. Re-evaluation of antibiotic treatment of strep-
tococcal pharyngitis. Curr Opin Pediatr. 2010;22:77-82.
21. Clegg HW, Ryan AG, Dallas SD, et al. Treatment of 
streptococcal pharyngitis with once-daily compared with 
twice-daily amoxicillin: a noninferiority trial. Pediatr 
Infect Dis J. 2006;25:761-767.
542  Clinical Pediatrics 50(6)
22. Feder HM Jr, Gerber MA, Randolph MF, Stelmach PS, 
Kaplan EL. Once-daily therapy for streptococcal pharyn-
gitis with amoxicillin. Pediatrics. 1999;103:47-51.
23. Lennon DR, Farrell E, Martin DR, Stewart JM. Once-
daily amoxicillin versus twice-daily penicillin V in group 
A beta-haemolytic streptococcal pharyngitis. Arch Dis 
Child. 2008;93:474-478.
24. Shvartzman P, Tabenkin H, Rosentzwaig A, Dolginov F. 
Treatment of streptococcal pharyngitis with amoxycillin 
once a day. BMJ. 1993;306:1170-1172.
25. Rimoin AW, Hamza HS, Vince A, et al. Evaluation of the 
WHO clinical decision rule for streptococcal pharyngitis. 
Arch Dis Child. 2005;90:1066-1070.
26. Rimoin AW, Walker CL, Chitale RA, et al. Variation in 
clinical presentation of childhood group A streptococcal 
pharyngitis in four countries. J Trop Pediatr. 2008;54: 
308-312.
27. Markowitz M, Gordis L. A mail-in technique for detect-
ing penicillin in urine: application to the study of main-
tenance of prophylaxis in rheumatic fever patients. 
Pediatrics. 1968;41:151-153.
28. Johnson DR, Kaplan EL, Sramek J, et al. Laboratory 
Diagnosis of Group A Streptococcal Infections. Geneva, 
Switzerland: World Health Organization; 1997.
29. Daly JA, Korgenski EK, Munson AC, Llausas-Magana E. 
Optical immunoassay for streptococcal pharyngitis: 
evaluation of accuracy with routine and mucoid strains 
associated with acute rheumatic fever outbreak in the 
intermountain area of the United States. J Clin Microbiol. 
1994;32: 531-532.
30. Harbeck RJ. Evaluation of two rapid antigen assays, Bio-
Star Strep A OIA and Pacific Biotech CARDS O.S., and 
culture for detection of group A streptococci in throat 
swabs. J Clin Microbiol. 1995;33:3365-3367.
31. Roe M, Kishiyama C, Davidson K, Schaefer L, Todd J. 
Comparison of BioStar Strep A OIA optical immune 
assay, Abbott TestPack Plus Strep A, and culture with 
selective media for diagnosis of group A streptococcal 
pharyngitis. J Clin Microbiol. 1995;33:1551-1553.
32. Gerber MA, Tanz RR, Kabat W, et al. Optical immunoassay 
test for group A beta-hemolytic streptococcal pharyngi-
tis. An office-based, multicenter investigation. JAMA. 
1997;277:899-903.
33. Hart AP, Buck LL, Morgan S, Saverio S, McLaughlin JC. 
A comparison of the BioStar Strep A OIA rapid antigen 
assay, group A Selective Strep Agar (ssA), and Todd-
Hewitt broth cultures for the detection of group A Strepto-
coccus in an outpatient family practice setting. Diagn 
Microbiol Infect Dis. 1997;29:139-145.
34. SAS. SAS v9.1. Cary, NC: SAS Corporation; 2002.
35. STATA. STATA 7.0. College Station, TX: STATA 
Coporation; 2001.
36. Kaplan EL, Oakes JM, Johnson DR. Unexpected indi-
vidual clinical site variation in eradication rates of group 
A streptococci by penicillin in multisite clinical trials. 
Pediatr Infect Dis J. 2007;26:1110-1116.
37. el-Kholy AM, Sorour AH, Rotta J, Guirguirs N. Group 
A beta hemolytic streptococci in skin lesions among an 
Egyptian school children population. J Hyg Epidemiol 
Microbiol Immunol. 1973;17:316-322.
38. Kaplan EL, Johnson DR. Unexplained reduced microbio-
logical efficacy of intramuscular benzathine penicillin G 
and of oral penicillin V in eradication of group a strep-
tococci from children with acute pharyngitis. Pediatrics. 
2001;108:1180-1186.
39. Pichichero ME. Explanations and therapies for penicillin 
failure in streptococcal pharyngitis. Clin Pediatr (Phila). 
1992;31:642-649.
40. Ovetchkine P, Levy C, de la Rocque F, Boucherat M, 
Bingen E, Cohen R. Variables influencing bacteriologi-
cal outcome in patients with streptococcal tonsillophar-
yngitis treated with penicillin V. Eur J Pediatr. 2002;161: 
365-367.
41. Altamimi S, Khalil A, Khalaiwi KA, Milner R, Pusic 
MV, Al Othman MA. Short versus standard duration anti-
biotic therapy for acute streptococcal pharyngitis in chil-
dren. Cochrane Database Syst Rev. 2009(1):CD004872. 
doi:10.1002/14651858.CD004872.pub2.
